MTMaja Brøgger Thomassen

Maja Brøgger Thomassen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maja Brøgger Thomassen has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A new HOPE for hypoplastic left heart syndrome: Technique for primary en-bloc heart and aorta transplant with hypothermic oxygenated recovery of a DCD heart

    by Maja Brøgger Thomassen, Niels Moeslund, Alan McCheyne, Chris Bivona, Henrik Henriksson, James Warburton, Klaes Vincent Lenbroch, Lukas Helming, Matthew Walker, Marx Runge, et al.

  • Open Access

    Myocardial metabolism during DCD heart donation and transplantation assessed by microdialysis

    by Maja Brøgger Thomassen, Klaes Vincent Lenbroch, Johanne Gade Lilleøre, Shan Awzhin Ali, Niels Moeslund, Per Lehnert, Mats Bue, Maiken Stilling, Roni Ranghøj Nielsen, Tor Skibsted Clemmensen, et al.

  • Open Access

    HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion

    by Nicholas J.S. Chilvers, Katrien Vandendriessche, Niels Moeslund, Marius Berman, Janne Brouckaert, Tanveer Butt, Barbara Cardoso, Bjorn Cools, David Crossland, John Dark, et al.


  • Timing of Antimicrobial Prophylaxis and Tourniquet Inflation

    by Pelle Hanberg, Mats Bue, Kristina Öbrink-Hansen, Maja Thomassen, Kjeld Søballe, Maiken Stilling

    Background: Tourniquets are widely used during extremity surgery. In order to prevent surgical site infection, correct timing of antimicrobial prophylaxis and tourniquet inflation is important. We aimed to evaluate the time for which the free drug concentration of cefuroxime is maintained above the minimum inhibitory concentration (t > MIC) in porcine subcutaneous adipose tissue and calcaneal cancellous bone during 3 clinically relevant tourniquet application scenarios. Methods: Twenty-four female Danish Landrace pigs were included. Microdialysis catheters were placed bilaterally for sampling of cefuroxime concentrations in calcaneal cancellous bone and subcutaneous adipose tissue, and a tourniquet was applied to a randomly picked leg of each pig. Subsequently, the pigs were randomized into 3 groups to receive 1.5 g of cefuroxime by intravenous injection 15 minutes prior to tourniquet inflation (Group A), 45 minutes prior to tourniquet inflation (Group B), and at the time of tourniquet release (Group C). The tourniquet duration was 90 minutes in all groups. Dialysates and venous blood samples were collected for 8 hours after cefuroxime administration. Cefuroxime and various ischemic marker concentrations were quantified. Results: Cefuroxime concentrations were maintained above the clinical breakpoint MIC for Staphylococcus aureus (4 µg/mL) in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet duration in Groups A and B. Cefuroxime administration at the time of tourniquet release (Group C) resulted in concentrations of >4 µg/mL for approximately of 3.5 hours in the tissues on the tourniquet side. Furthermore, tourniquet application induced ischemia (increased lactate:pyruvate ratio) and cell damage (increased glycerol) in subcutaneous adipose tissue and calcaneal cancellous bone. Tissue ischemia was sustained for 2.5 hours after tourniquet release in calcaneal cancellous bone. Conclusions: Administration of cefuroxime (1.5 g) in the 15 to 45-minute window prior to tourniquet inflation resulted in sufficient concentrations in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet application. Furthermore, tourniquet-induced tissue ischemia fully resolved 2.5 hours after tourniquet release. Clinical Relevance: Cefuroxime administration 15 to 45 minutes prior to tourniquet inflation seems to be a safe window. If the goal is to maintain postoperative cefuroxime concentrations above relevant MIC values, our results suggest that a second dose of cefuroxime should be administered at the time of tourniquet release.


  • Local concentrations of gentamicin obtained by microdialysis after a controlled application of a GentaColl sponge in a porcine model

    by Maja B. Thomassen, Pelle Hanberg, Maiken Stilling, Klaus K. Petersen, Kjeld Søballe, Lasse B. Krag, Carsten S. Højskov, Mats Bue

    Local treatment with gentamicin may be an important tool in the prevention and treatment of surgical site infections in high‐risk procedures and patients. The aim of this study was to evaluate the pharmacokinetic profile of gentamicin in bone and surrounding tissue, released from a controlled application of a GentaColl sponge in a porcine model. In eight female pigs, a GentaColl sponge of 10 × 10 cm (1.3 mg gentamicin/cm2) was placed in a cancellous bone cavity in the proximal tibia. Microdialysis was used for sampling of gentamicin concentrations over 48 hours from the cavity with the implanted GentaColl sponge, cancellous bone parallel to the cavity over and under the epiphyseal plate, cortical bone, the intramedullary canal, subcutaneous tissue, and the joint cavity of the knee. Venous blood samples were obtained as reference. The main finding was a mean peak drug concentration (95% CI) of gentamicin in the cancellous bone cavity containing the implanted GentaColl sponge of 11 315 (9049‐13 581) μg/mL, persisting above 1000 μg/mL until approximately 40 hours after application. Moreover, the concentrations were low (<1 μg/mL) in the surrounding tissues as well as in plasma. The mean peak gentamicin concentration from the cancellous bone cavity after a controlled application of a GentaColl sponge was high and may be adequate for the prevention of biofilm formation. However, high MIC strains and uncontrolled application of the GentaColl sponge may jeopardize this conclusion.